
Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT
Arcturus Therapeutics Holdings stock price today
Arcturus Therapeutics Holdings stock price monthly change
Arcturus Therapeutics Holdings stock price quarterly change
Arcturus Therapeutics Holdings stock price yearly change
Arcturus Therapeutics Holdings key metrics
Market Cap | 417.14M |
Enterprise value | 412.20M |
P/E | 77.06 |
EV/Sales | 1.72 |
EV/EBITDA | -7.03 |
Price/Sales | 2.99 |
Price/Book | 2.63 |
PEG ratio | 0.73 |
EPS | -3.91 |
Revenue | 113.75M |
EBITDA | -106.49M |
Income | -104.16M |
Revenue Q/Q | -59.11% |
Revenue Y/Y | -59.40% |
Profit margin | -26.59% |
Oper. margin | -25.3% |
Gross margin | 5.61% |
EBIT margin | -25.3% |
EBITDA margin | -93.62% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArcturus Therapeutics Holdings stock price history
Arcturus Therapeutics Holdings stock forecast
Arcturus Therapeutics Holdings financial statements
$73
Potential upside: 318.57%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 9.56M | -52.55M | -549.4% |
---|---|---|---|
Sep 2023 | 43.37M | -16.22M | -37.4% |
Dec 2023 | 28.21M | -8.57M | -30.39% |
Mar 2024 | 32.59M | -26.81M | -82.27% |
Jun 2023 | 430646000 | 145.47M | 33.78% |
---|---|---|---|
Sep 2023 | 457650000 | 177.58M | 38.8% |
Dec 2023 | 429402000 | 150.88M | 35.14% |
Mar 2024 | 418849000 | 154.87M | 36.98% |
Jun 2023 | 50.80M | -354K | 94K |
---|---|---|---|
Sep 2023 | -32.40M | -981K | 21.84M |
Dec 2023 | -544.67K | -837.07K | -17.98M |
Mar 2024 | -5.55M | -240K | 2.18M |
Arcturus Therapeutics Holdings alternative data
Aug 2023 | 170 |
---|---|
Sep 2023 | 170 |
Oct 2023 | 170 |
Nov 2023 | 170 |
Dec 2023 | 170 |
Jan 2024 | 170 |
Feb 2024 | 170 |
Mar 2024 | 180 |
Apr 2024 | 180 |
May 2024 | 180 |
Jun 2024 | 180 |
Jul 2024 | 180 |
Arcturus Therapeutics Holdings other data
Period | Buy | Sel |
---|---|---|
Mar 2024 | 0 | 26000 |
Jun 2024 | 0 | 76114 |
Oct 2024 | 0 | 12000 |
Quarter | Transcript |
---|---|
Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Joseph E. Payne M.Sc. (1972) Founder, Pres, Chief Executive Officer & Director | $950,000 |
Dr. Steven George Hughes M.B.A., M.D. (1967) Chief Medical Officer | $664,000 |
Dr. Padmanabh Chivukula (1979) Founder, Chief Scientific Officer, Chief Operating Officer & Sec. | $640,000 |
Mr. Andrew H. Sassine (1964) Chief Financial Officer & Director | $640,000 |
Vertex: Poised For Long-Term Growth Driven By Multiple Pipeline Catalysts
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
Arcturus: H1 2024 Rare Disease Drug Data On Deck
From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey
Arcturus: Interim Readout Of Rare Disease Data In Coming Months
Arcturus: mRNA Therapies For Rare Diseases Accelerate Towards Proof Of Concept
Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
Unlocking Arcturus' Potential And De-Risking Through Partnerships
-
What's the price of Arcturus Therapeutics Holdings stock today?
One share of Arcturus Therapeutics Holdings stock can currently be purchased for approximately $17.44.
-
When is Arcturus Therapeutics Holdings's next earnings date?
Unfortunately, Arcturus Therapeutics Holdings's (ARCT) next earnings date is currently unknown.
-
Does Arcturus Therapeutics Holdings pay dividends?
No, Arcturus Therapeutics Holdings does not pay dividends.
-
How much money does Arcturus Therapeutics Holdings make?
Arcturus Therapeutics Holdings has a market capitalization of 417.14M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 23.33% to 157.75M US dollars.
-
What is Arcturus Therapeutics Holdings's stock symbol?
Arcturus Therapeutics Holdings Inc. is traded on the NASDAQ under the ticker symbol "ARCT".
-
What is Arcturus Therapeutics Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Arcturus Therapeutics Holdings?
Shares of Arcturus Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Arcturus Therapeutics Holdings's key executives?
Arcturus Therapeutics Holdings's management team includes the following people:
- Mr. Joseph E. Payne M.Sc. Founder, Pres, Chief Executive Officer & Director(age: 53, pay: $950,000)
- Dr. Steven George Hughes M.B.A., M.D. Chief Medical Officer(age: 58, pay: $664,000)
- Dr. Padmanabh Chivukula Founder, Chief Scientific Officer, Chief Operating Officer & Sec.(age: 46, pay: $640,000)
- Mr. Andrew H. Sassine Chief Financial Officer & Director(age: 61, pay: $640,000)
-
Is Arcturus Therapeutics Holdings founder-led company?
Yes, Arcturus Therapeutics Holdings is a company led by its founders Mr. Joseph E. Payne M.Sc. and Dr. Padmanabh Chivukula.
-
How many employees does Arcturus Therapeutics Holdings have?
As Jul 2024, Arcturus Therapeutics Holdings employs 180 workers.
-
When Arcturus Therapeutics Holdings went public?
Arcturus Therapeutics Holdings Inc. is publicly traded company for more then 12 years since IPO on 22 May 2013.
-
What is Arcturus Therapeutics Holdings's official website?
The official website for Arcturus Therapeutics Holdings is arcturusrx.com.
-
Where are Arcturus Therapeutics Holdings's headquarters?
Arcturus Therapeutics Holdings is headquartered at 10628 Science Center Drive, San Diego, CA.
-
How can i contact Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings's mailing address is 10628 Science Center Drive, San Diego, CA and company can be reached via phone at 858 900 2660.
-
What is Arcturus Therapeutics Holdings stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Arcturus Therapeutics Holdings in the last 12 months, the avarage price target is $73. The average price target represents a 318.57% change from the last price of $17.44.
Arcturus Therapeutics Holdings company profile:

Arcturus Therapeutics Holdings Inc.
arcturusrx.comNASDAQ
180
Biotechnology
Healthcare
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
San Diego, CA 92121
CIK: 0001768224
ISIN: US03969T1097
CUSIP: 03969T109